agsandrew-shutterstock-com-1

agsandrew / Shutterstock.com

9 April 2015Genetics

The CRISPR patent war

Research into genome-editing technologies has progressed to a point where we can read the strains of DNA that exist in almost every cell of our bodies as if they were on a word processor and take faulty, disease-causing genes out of a sequence and replace them with functioning ones.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

USPTO ignites CRISPR/Cas9 patent battle

13 January 2016 Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.

Why CRISPR may define pre- and post-AIA changes

17 September 2015 Many players are piling into the scrum surrounding the patent eligibility of CRISPR technology. Mercedes Meyer of Drinker Biddle & Reath discusses the legal implications of CRISPR as a potential groundbreaking foundation technology.

More on this story

USPTO ignites CRISPR/Cas9 patent battle

13 January 2016 Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.

Why CRISPR may define pre- and post-AIA changes

17 September 2015 Many players are piling into the scrum surrounding the patent eligibility of CRISPR technology. Mercedes Meyer of Drinker Biddle & Reath discusses the legal implications of CRISPR as a potential groundbreaking foundation technology.

More on this story

USPTO ignites CRISPR/Cas9 patent battle

13 January 2016 Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.

Why CRISPR may define pre- and post-AIA changes

17 September 2015 Many players are piling into the scrum surrounding the patent eligibility of CRISPR technology. Mercedes Meyer of Drinker Biddle & Reath discusses the legal implications of CRISPR as a potential groundbreaking foundation technology.

More features

Sanofi successfully challenges rare disease patent in Europe

Broad Institute wins appeal to restore CRISPR patent in Europe

AstraZeneca forced to clarify deal terms in row with university

Biotech seeks to stop Kirkland from representing rival in Eylea dispute

Diverging in the detail: UPC local divisions and Court of Appeal take different paths

Novo Nordisk patent lapse opens door for Canadian Ozempic generics

UK govt sets sights on being AI drug discovery ‘world leader’

Sheppard Mullin expands practice with Perkins Coie trio